Theme

Session Title

Presentation
No.

Abstract
No.

SpeakerCountry

ATRB-IS-01

SPKR-22ATRT – update on biology, subgroups, targets, and potential clinical implications

Marcel Kool

Germany

ATRB-O-02

ATRT-13Different cells of origin pave the way for molecular heterogeneity in rhabdoid tumors

Monika Graf

Germany

ATRB-O-03

ATRT-14

Macrophage-tumor cell interaction promotes ATRT progression and chemoresistance

Viktoria Melcher

Germany

ATRB-O-04

ATRT-25

Integrated quantitative SWATH-MS proteomics analysis of ATRTs uncovers new therapeutic
opportunities

Martina Finetti

USA

ATRB-P-05

ATRT-24

Cell surface proteome analysis of ATRT identifies targets for immunotherapy

Siddhartha Mitra

USAATRB-P-06

ATRT-06

SMARCB1 loss driven non-canonical PRC1 activity regulates differentiation in AtypicalTeratoid Rhabdoid Tumors (ATRT).

Irina Alimova

USA

ATRB-O-07

ATRT-33

Enabling rapid classification of ATRT with Nanostring nCounter platform

Ben HoCanada

ATRB-P-08

ATRT-28

Single nuclei sequencing reveals the different phenotypic composition of the ATRT subgroups Pascal Johann

Germany

ATRB-O-09

ATRT-16Modelling ATRT through SWI/SNF complex deficiency in genetically-engineered mousemodels

Andrew Bondoc

CanadaATRB-O-10

ATRT-18

SHH-subtype Atypical Teratoid/Rhabdoid Tumors are selectively sensitive to gemcitabine
treatment

Dennis Metselaar

Netherlands

ATRB-P-11

ATRT-22

High-throughput drug screening of FDA-approved cancer drugs reveals potential therapeutic
approaches for atypical teratoid rhabdoid tumour

Wai Chin Chong

Australia

ATRB-O-12

ATRT-32

Genome-wide CRISPR and small-molecule screens uncover targetable dependencies inAT/RTs

Daniel MerkGermany

ATRB-P-13

ATRT-11Prevalence of germline variants in SMARCB1 including somatic mosaicism in AT/RT andother rhabdoid tumors

Ryota Shirai

JapanATRB-P-14

ATRT-15

LY6D – a candidate for nanoparticle-based targeted therapies of ATRT

Lea Hagemeier

Germany

ATRB-P-15

ATRT-19

Epigenetic reprogramming leads to innate immune pathway activation in AT/RT

Seethalakshmi Hariharan

USA

ATRB-P-16

ATRT-27

Cost-effective assays to subgroup ATRT in the daily routine

María-Jesús Lobon-Iglesias

FranceATRB-P-17

ATRT-03

Identification of microRNA-based prognostic biomarkers and candidate therapeutic agents forYang Zhang
atypical teratoid/rhabdoid tumor

China

ATRB-P-18

ATRT-20

CDK7 inhibition in AT/RT

Andrew Morin

USA

ATRB-P-19

ATRT-23

The dual mTORC1/2 inhibitor Sapanisertib disrupts the NRF2-mediated stress response andcombines synergistically with the BH3 mimetic Obatoclax to extend AT/RT survival

Jeffrey Rubens

USA

ATRB-P-20

ATRT-01

Upregulation of protein synthesis and proteasome degradation confers sensitivity toproteasome inhibitor bortezomib in Myc-atypical teratoid/rhabdoid tumors

Minh-Huy Tran

TaiwanATRB-P-21

ATRT-17

Targeting glutamine metabolism lowers methylation potencials in AT/RT and synergize withtazemetostat

Satoshi Nakata

USAATRB-P-22

ATRT-02

MEK/ERK signalling dependency in atypical teratoid rhabdoid tumours

Hui (Claire) Shi

Australia

ATRB-P-23

ATRT-09

Identification of hub genes in atypical teratoid/rhabdoid tumors by multiple-microarray analysis Wei Liu

China

ATRB-P-24

ATRT-21

Rhabdoid predisposition syndrome: report of molecular profiles and treatment approach inthree children with synchronous atypical teratoid/rhabdoid tumor and malignant rhabdoidtumor

Margaret ShataraUSA

ATRC-P-01

ATRT-05

Results of multicenter trial concerning the treatment of children with AtypicalTeratoid/Rhabdoid Tumors (ATRT) of the central nervous system

Olga Zheludkova

Russia

ATRC-P-02

ATRT-08

A phase II study of continuous low dose panobinostat in paediatric patients with malignant
rhabdoid tumors/atypical teratoid rhabdoid tumors

Paul Wood

Australia

ATRC-P-03

ATRT-26

Meta-analysis of treatment modalities in metastatic atypical teratoid/rhabdoid tumors inchildren

Mohamed AbdelBaki

USAATRC-P-04

ATRT-30

Retrospective analysis of children with atypical teratoid rhabdoid tumor treated according toACNS0333

Lindsey Hoffman

USAATRC-P-05

ATRT-07

High-dose chemotherapy and autologous stem cell transplantation for an adult presentation ofMaciej Mrugala
the atypical teratoid-rhabdoid tumor (ATRT)USA

ATRC-P-06

ATRT-31

Successful multimodality management of ATRT of the lower dorsal spine with spinal drop
metastasis

Ahitagni Biswas

India

ATRC-P-07

ATRT-04

Inherited rhabdoid predisposition syndrome: a case of choroid plexus carcinoma and atypicalteratoid rhabdoid tumor in siblings

Alexis JuddUSA

ATRC-P-08

ATRT-10

Atypical teratoid/rhabdoid tumor of the pineal region in a pediatric patient

Carlos Almeida, Jr.

BrazilAT/RT (basic)

Tumor-type
specific Sessions

Lecture title

AT/RT (clinical)